Clinical value of biomarkers in diagnosis and treatment of idiopathic pulmonary fibrosis / 南方医科大学学报
Journal of Southern Medical University
;
(12): 1062-1065, 2020.
Article
in Chinese
| WPRIM
| ID: wpr-828927
ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial pneumonia characterized by progressive accumulation of fibroblastic foci and destruction of the alveolar structure. Due to an incomplete understanding of the mechanism of the occurrence and progression of IPF, currently no effective means have been available for its early screening or treatment. With a poor overall prognosis, the patients with IPF have a median survival of only 2-4 years. In recent years, several studies have confirmed that dozens of molecules are involved in the development of IPF and can be used as potential biomarkers. These biomarkers play important roles in early diagnosis (such as SP-D, MMP-7, and osteopontin), prognostic evaluation (such as telomerase length, KL-6, mtDNA, HSP-70, LOXL2, CXCL13, miRNA, ICAM-1, and CCL18), and guiding treatment of IPF (such as TOLLIP rs3750920 genotype, SAMS score, and SP-D), and also provide potential therapeutic targets (such as TERT, TERR, RTEC, and PARN).
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Biomarkers
/
Disease Progression
/
Matrix Metalloproteinase 7
/
Intracellular Signaling Peptides and Proteins
/
Idiopathic Pulmonary Fibrosis
/
Amino Acid Oxidoreductases
Type of study:
Diagnostic study
/
Prognostic study
/
Screening study
Limits:
Humans
Language:
Chinese
Journal:
Journal of Southern Medical University
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS